The role of prolactin levels in metabolic syndrome: a systematic review
DOI:
https://doi.org/10.12775/QS.2024.22.54607Keywords
prolactin, hyperprolactinemia, hypoprolactinemia, metabolic syndrome, diabetes mellitus, obesityAbstract
Introduction and purpose: Prolactin is primarily associated with lactation and gonadal function, but it also has metabolic effects. Recent research shows prolactin's role in food intake, body weight, glucose, and lipid profile. Both low and excessive prolactin levels can lead to metabolic dysfunctions such as metabolic syndrome, type 2 DM, and dyslipidemia. Dopamine agonists, like cabergoline, used to treat hyperprolactinemia, may help balance metabolic homeostasis, likely due to their effect on prolactin. This study aims to synthesize current research on prolactin's metabolic effects, focusing on metabolic syndrome.
State of knowledge: Metabolic syndrome is a cluster of dysfunctions like central obesity, atherogenic dyslipidemia, hypertension, and insulin resistance. It increases the risk of diabetes and cardiovascular diseases, affecting a quarter of the European population. Different combinations of metabolic syndrome components require various treatment approaches. New research focuses on prolactin and dopamine agonists in its pathogenesis and treatment.
Materials and methods: This literature review is based on PubMed materials using keywords “prolactin,” “hyperprolactinemia,” “hypoprolactinemia,” “metabolic syndrome,” “diabetes mellitus,” “obesity.”
Conclusions: This study highlights prolactin's importance in metabolic homeostasis, finding a positive correlation between both low and high prolactin levels and metabolic syndrome. However, gender differences and the pathogenesis of metabolic disorders should be further explored.
References
Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, et al.; Metabolic Syndrome and Arteries Research (MARE) Consortium. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015 Apr;22(4):486-91. doi: 10.1177/2047487314525529. Epub 2014 Mar 19. PMID: 24647805; PMCID: PMC4544872.
Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013 Aug 20;62(8):697-703. doi: 10.1016/j.jacc.2013.05.064. Epub 2013 Jun 27. PMID: 23810877; PMCID: PMC3756561.
Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab Syndr Relat Disord. 2013 Apr;11(2):71-80. doi: 10.1089/met.2012.0122. Epub 2012 Dec 18. PMID: 23249214.
Xu H, Li X, Adams H, Kubena K, Guo S. Etiology of Metabolic Syndrome and Dietary Intervention. Int J Mol Sci. 2018 Dec 31;20(1):128. doi: 10.3390/ijms20010128. PMID: 30602666; PMCID: PMC6337367.
Malin SK, Finnegan S, Fealy CE, Filion J, Rocco MB, Kirwan JP. β-Cell dysfunction is associated with metabolic syndrome severity in adults. Metab Syndr Relat Disord. 2014 Mar;12(2):79-85. doi: 10.1089/met.2013.0083. Epub 2013 Nov 27. PMID: 24283920; PMCID: PMC3942708.
Muniyappa R, Madan R, Varghese RT. Assessing Insulin Sensitivity and Resistance in Humans. [Updated 2021 Aug 9]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278954/
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996 Feb 1;334(5):292-5. doi: 10.1056/NEJM199602013340503. PMID: 8532024.
Barba G, Russo O, Siani A, Iacone R, Farinaro E, Gerardi MC, Russo P, Della Valle E, Strazzullo P. Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. Obes Res. 2003 Jan;11(1):160-6. doi: 10.1038/oby.2003.25. PMID: 12529499.
Meyer LK, Ciaraldi TP, Henry RR, Wittgrove AC, Phillips SA. Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte. 2013 Oct 1;2(4):217-26. doi: 10.4161/adip.24953. Epub 2013 May 7. PMID: 24052897; PMCID: PMC3774697.
von Frankenberg AD, do Nascimento FV, Gatelli LE, Nedel BL, Garcia SP, de Oliveira CS, Saddi-Rosa P, Reis AF, Canani LH, Gerchman F. Major components of metabolic syndrome and adiponectin levels: a cross-sectional study. Diabetol Metab Syndr. 2014 Feb 26;6(1):26. doi: 10.1186/1758-5996-6-26. PMID: 24568287; PMCID: PMC3941563.
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786. PMID: 35054972; PMCID: PMC8775991.
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000 Oct;80(4):1523-631. doi: 10.1152/physrev.2000.80.4.1523. PMID: 11015620
Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato J Jr. Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience. 2014 Feb 14;259:71-83. doi: 10.1016/j.neuroscience.2013.11.050. Epub 2013 Dec 4. PMID: 24316468.
Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N, Breant B, Kelly PA. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology. 2002 Apr;143(4):1378-85. doi: 10.1210/endo.143.4.8722. PMID: 11897695.
Ruiz-Herrera X, de Los Ríos EA, Díaz JM, Lerma-Alvarado RM, Martínez de la Escalera L, López-Barrera F, Lemini M, Arnold E, Martínez de la Escalera G, Clapp C, Macotela Y. Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males. Endocrinology. 2017 Jan 1;158(1):56-68. doi: 10.1210/en.2016-1444. PMID: 27805870.
Thapa S, Bhusal K. Hyperprolactinemia. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537331/
Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013 Jul;6(3):168-75. doi: 10.4103/0974-1208.121400. PMID: 24347930; PMCID: PMC3853872.
Leca BM, Mytilinaiou M, Tsoli M, Epure A, Aylwin SJB, Kaltsas G, Randeva HS, Dimitriadis GK. Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. Sci Rep. 2021 May 7;11(1):9801. doi: 10.1038/s41598-021-89256-7. PMID: 33963239; PMCID: PMC8105338.
Yatavelli RKR, Bhusal K. Prolactinoma. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459347/
Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf). 1998 May;48(5):547-53. doi: 10.1046/j.1365-2265.1998.00403.x. PMID: 9666865.
Hofbauer S, Horka L, Seidenberg S, Da Mutten R, Regli L, Serra C, Beuschlein F, Erlic Z. Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center. Front Endocrinol (Lausanne). 2024 Apr 5;15:1363939. doi: 10.3389/fendo.2024.1363939. PMID: 38645431; PMCID: PMC11026551.
Creemers LB, Zelissen PM, van 't Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh). 1991 Oct;125(4):392-6. doi: 10.1530/acta.0.1250392. PMID: 1957557.
Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014 Jun;15(6):367-78. doi: 10.1038/nrn3745. PMID: 24840801; PMCID: PMC4076116.
Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato J Jr. Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience. 2014 Feb 14;259:71-83. doi: 10.1016/j.neuroscience.2013.11.050. Epub 2013 Dec 4. PMID: 24316468.
Naef L, Woodside B. Prolactin/Leptin interactions in the control of food intake in rats. Endocrinology. 2007 Dec;148(12):5977-83. doi: 10.1210/en.2007-0442. Epub 2007 Sep 13. PMID: 17872372.
Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006 Apr;17(3):110-6. doi: 10.1016/j.tem.2006.02.005. Epub 2006 Mar 6. PMID: 16517173.
Gierach M, Bruska-Sikorska M, Rojek M, Junik R. Hyperprolactinemia and insulin resistance. Endokrynol Pol. 2022;73(6):959-967. doi: 10.5603/EP.a2022.0075. PMID: 36621922.
Wu TH, Lin CH, Goh KK, Chen CY, Chen CH, Lane HY, Lu ML. The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment. Front Pharmacol. 2021 Aug 5;12:718800. doi: 10.3389/fphar.2021.718800. PMID: 34421613; PMCID: PMC8374865.
Petruzzelli MG, Margari M, Peschechera A, de Giambattista C, De Giacomo A, Matera E, Margari F. Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis. BMC Psychiatry. 2018 Aug 1;18(1):246. doi: 10.1186/s12888-018-1827-3. PMID: 30068291; PMCID: PMC6090964.
Pala NA, Laway BA, Misgar RA, Shah ZA, Gojwari TA, Dar TA. Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):177-81. doi: 10.4103/2230-8210.176346. PMID: 27042412; PMCID: PMC4792017.
Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1120-6. doi: 10.1016/j.bbrc.2005.04.026. PMID: 15882993.
Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011 Sep;14(3):199-207. doi: 10.1007/s11102-010-0277-9. PMID: 21128120.
Sheoran A, Agarwal N, Mahto SK, Gupta PK, Gupta K, Sharma N. Study of Association of Serum Prolactin Levels with Insulin Resistance in Type 2 Diabetes Mellitus Patients. Indian J Endocrinol Metab. 2023 Jul-Aug;27(4):351-356. doi: 10.4103/ijem.ijem_440_22. Epub 2023 Jun 30. PMID: 37867980; PMCID: PMC10586557.
Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009 Sep 17;361(12):1152-63. doi: 10.1056/NEJMoa0804381. Epub 2009 Aug 5. PMID: 19657112; PMCID: PMC2774225.
Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988 Sep;67(3):460-4. doi: 10.1210/jcem-67-3-460. PMID: 2842359.
Pala NA, Laway BA, Misgar RA, Dar RA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015 Nov 14;7:99. doi: 10.1186/s13098-015-0094-4. PMID: 26583049; PMCID: PMC4650139.
Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG. The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Hum Reprod. 1999 Feb;14(2):285-7. doi: 10.1093/humrep/14.2.285. PMID: 10099964.
Zhang L, Curhan GC, Forman JP. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens. 2010 Jul;28(7):1400-5. doi: 10.1097/HJH.0b013e328339f254. PMID: 20453663; PMCID: PMC3139424.
Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, Surico N, Vacca G. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology. 2007 Aug;148(8):4080-90. doi: 10.1210/en.2006-1577. Epub 2007 Apr 26. PMID: 17463060.
Chang AS, Grant R, Tomita H, Kim HS, Smithies O, Kakoki M. Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12538-12543. doi: 10.1073/pnas.1615051113. Epub 2016 Oct 17. PMID: 27791173; PMCID: PMC5098649.
Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P, Pivonello C, Negri M, Mannarino T, Giordano C, Gasperi M, Colao A, Pivonello R. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299-310. doi: 10.1159/000357810. Epub 2013 Dec 17. PMID: 24355865.
Kok P, Roelfsema F, Frölich M, van Pelt J, Stokkel MP, Meinders AE, Pijl H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1038-43. doi: 10.1152/ajpendo.00567.2005. Epub 2006 Jun 27. PMID: 16803851.
Krysiak R, Okopien B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):251-6. doi: 10.1111/bcpt.12307. Epub 2014 Sep 11. PMID: 25123447.
Pirchio R, Auriemma RS, Solari D, Arnesi M, Pivonello C, Negri M, de Angelis C, Cavallo LM, Cappabianca P, Colao A, Pivonello R. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. Front Endocrinol (Lausanne). 2021 Nov 30;12:769744. doi: 10.3389/fendo.2021.769744. PMID: 34917030; PMCID: PMC8670228.
Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S17-24. doi: 10.4103/2230-8210.83058. PMID: 21847449; PMCID: PMC3152192.
Birhan MT, Ayele TM, Abebe FW, Dgnew FN. Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review. Diabetol Metab Syndr. 2023 Jul 6;15(1):151. doi: 10.1186/s13098-023-01073-2. PMID: 37415177; PMCID: PMC10324265.
Krysiak R, Kowalcze K, Okopień B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020 Oct;93(4):482-488. doi: 10.1111/cen.14283. Epub 2020 Jul 26. PMID: 32654174.
Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009 May;6(5):1457-66. doi: 10.1111/j.1743-6109.2008.01206.x. Epub 2009 Feb 10. PMID: 19210705.
Krysiak R, Kowalcze K, Okopień B. Cardiometabolic profile of young women with hypoprolactinemia. Endocrine. 2022 Oct;78(1):135-141. doi: 10.1007/s12020-022-03145-1. Epub 2022 Jul 29. PMID: 35906342; PMCID: PMC9474346.
Krysiak R, Kowalcze K, Okopień B. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study. Cardiology. 2022;147(5-6):497-506. doi: 10.1159/000527333. Epub 2022 Oct 4. PMID: 36195057; PMCID: PMC9808652.
Li J, Rice MS, Huang T, Hankinson SE, Clevenger CV, Hu FB, Tworoger SS. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 2018 Dec;61(12):2549-2560. doi: 10.1007/s00125-018-4733-9. Epub 2018 Oct 11. PMID: 30306190; PMCID: PMC6309828.
Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013 Mar 21;13:12. doi: 10.1186/1472-6823-13-12. PMID: 23517652; PMCID: PMC3614874.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Karolina Korta, Anna Szeliga, Karolina Oluszczak, Agata Szostak, Liliana Dyląg, Konrad Wawszkowicz, Kinga Szopińska, Maria Janina Śmigielska-Mikołajczyk, Weronika Łowicka, Magdalena Graca
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 110
Number of citations: 0